Effects of dairy products naturally enriched with cis-9,trans-11 conjugated linoleic acid on the blood lipid profile in healthy middle-aged men

Conjugated linoleic acid (CLA) is a collective term for a mixture of positional and geometric isomers of conjugated dienoic derivatives of linoleic acid. CLA has received considerable attention as a result of animal experiments that report anti-carcinogenic, anti-atherogenic and anti-diabetic properties, and modulation of body composition and immune function. Several studies of CLA supplementation in human subjects have now been published, but in contrast to animal studies there has been marked variation between reports on the health-related outcomes. The consensus from seventeen published studies in human subjects is that CLA does not affect body weight or body composition. Some detrimental effects of thetrans-10,cis-12 CLA isomer have also been reported in terms of altered blood lipid composition and impaired insulin sensitivity. Finally, CLA has only limited effects on immune functions in man. However, there have been reports of some interesting isomer-specific effects of CLA on the blood lipid profile, but not on immune function. These isomer-specific effects need further investigation. Until more is known, CLA supplementation in man should be considered with caution.

Download Full-text

FLUVASTATIN EFFECTS ON BLOOD CELL AGGREGATION IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA

CARDIOVASCULAR THERAPY AND PREVENTION ◽

10.15829/1728-8800-2013-2-18-24 ◽

2013 ◽

Vol 12 (2) ◽

pp. 18-24 ◽

Cited By ~ 1

Author(s):

I. N. Medvedev ◽

I. A. Skoryatina

Keyword(s):

Blood Cell ◽

Arterial Hypertension ◽

Lipid Profile ◽

Cell Membranes ◽

Blood Lipid ◽

Cell Aggregation ◽

Middle Aged ◽

Blood Lipid Profile ◽

One Year ◽

Blood Cell Aggregation

Aim.To investigate the effects of fluvastatin on the blood cell aggregation in patients with arterial hypertension (AH) and dyslipidemia (DLP).Material and methods.The main group (MG) included 32 middle-aged patients with Stage 1–2 AH (Risk 3) and Type IIb DLP. The control group (CG) included 26 healthy middle-aged people. All patients received fluvastatin (40 mg/d in the evening) and enalapril (10 mg twice per day). The assessment of clinical and laboratory parameters was performed at baseline, and after 4, 12, and 52 weeks of the therapy.Results.In MG patients, the disturbances of blood lipid profile and lipid component of blood cell membranes, together with activation of lipid peroxidation (LP) in blood cell membranes, was associated with an increased aggregation of erythrocytes, platelets, and leukocytes. The 52-week fluvastatin therapy somewhat improved blood lipid profile and reduced LP activity in both plasma and blood cells. However, these parameters failed to reach the levels observed in the CG. The one-year treatment with fluvastatin in the MG reduced, but not completely normalised the aggregation of erythrocytes, platelets, and leukocytes.Conclusion.Treating patients with AH and DLP with fluvastatin for one year significantly reduces, but not normalises blood cell aggregation.

Download Full-text